Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Non-transfusion-dependent thalassemia encompasses three clinically distinct forms -- beta-thalassaemia intermedia, hemoglobin ...

Yoltech Therapeutics Co. Ltd. has advanced YOLT-204 into the clinic for the treatment of transfusion-dependent β-thalassemia (TDT). If successful, YOLT-204 may provide an off-the-shelf curative ...

DelveInsight's report on Alpha Thalassemia provides a comprehensive analysis of the epidemiology and <a target=_blank href= ...

To prevent life-long agony, all couples must get a genetic test before planning a child, he added. Expressing concern over ...

Mumbai: Families of children undergoing treatment at BMC's low-cost thalassemia care and bone marrow transplant centre in ...

Pune: City doctors successfully retrieved white blood cells from a 20-month-old girl and transfused these into the blood of her elder sibling sufferin.

YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204, an investigational therapy for the ...

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and ...